Genomic and metabolomic advances in the identification of disease and adverse event biomarkers

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 605-615

  Mendrick, Donna L ^a   Schnackenberg, Laura ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Biomarker; Genomic; Medicine; Metabolomic; Metabonomic; Personalized; Pharmacogenomic

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALACTOSAMINE; GLYCOCHENODEOXYCHOLIC ACID; HOMOVANILLIC ACID; KIDNEY INJURY MOLECULE 1; MICRORNA; PARACETAMOL; TRASTUZUMAB;

ACUTE GRAFT REJECTION; BREAST CANCER; CANCER INVASION; COLORECTAL CANCER; CROHN DISEASE; GENE EXPRESSION PROFILING; GENOMICS; HEART TRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; METABOLOMICS; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOGENOMICS; PROGNOSIS; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REIMBURSEMENT; REVIEW; SYSTEMS BIOLOGY; ULCERATIVE COLITIS;

EID: 70450263593     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.43     Document Type: Review

References (105)

1. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001). ■■ Ground-breaking article exploring the efficacy rate of marketed compounds.
2. Woodcock J: The prospects for "personalized medicine" in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
3. US Department of Health and Human Services. Personalized Health Care: Pioneers, Partnerships, Progress. US Department of Health and Human Services, DC, USA (2008)
4. Laterza OF, Modur VR, Ladenson JH: Biomarkers of tissue injury. Biomarkers Med. 2, 81-92 (2008).
5. Goodsaid FM, Frueh FW, Mattes W: Strategic paths for biomarker qualification. Toxicology 245, 219-223 (2008).
6. Mattes WB , Walker EG: Translational toxicology and the work of the predictive safety testing consortium. Clin. Pharmacol. Ther. 85, 327-330 (2009).
7. Mattes WB: Public consortium efforts in toxicogenomics. In: Essential Concepts in Toxicogenomics. Mendrick DL, Mattes WB (Eds). Humana, NJ, USA, 221-238 (2008).
8. Biomarkers Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin.Pharmacol. Ther. 69, 89-95 (2001).
9. Leone AM, Kao LM, McMillian MK et al.: Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol. 20, 600-608 (2007).
10. Hultin-Rosenberg L, Jagannathan S, Nilsson KC et al.: Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36, 1122-1139 (2006).
11. Buck WR, Waring JF, Blomme EA:. Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: toxicogenomics in mechanistic toxicology. In: Essential Concepts in Toxicogenomics. Mendrick DL, Mattes WB (Eds). Humana, NJ, USA, 23-44 (2008).
12. Martin R, Rose D, Yu K, Barros S: Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7, 1003-1016 (2006).
13. Hunt JL: Molecular pathology in anatomic pathology practice: a review of basic principles. Arch. Pathol. Lab. Med. 132, 248-260 (2008).
14. Mendrick DL , Daniels KK: From the bench to the clinic and back again: translational biomarker discovery using in silico mining of pharmacogenomic data. Biomarkers Med. 1, 319-333 (2007).
15. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA: The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 147, 126-132 (2006).
16. Burczynski ME , Dorner AJ: Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7, 187-202 (2006). ■■ Excellent article on the use of transcriptomics to identify biomarkers in circulating blood cells.
17. Sharp FR, Xu H, Lit L et al.: Genomic profiles of stroke in blood. Stroke 38, 691-693 (2007).
18. Sharp FR, Xu H, Lit L et al.: The future of genomic profiling of neurological diseases using blood. Arch. Neurol. 63, 1529-1536 (2006).
19. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, Shalev AY: Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. Mol. Psychiatry 10, 500-513 (2005).
20. Burczynski ME, Peterson RL, Twine NC et al.: Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 8, 51-61 (2006).
21. Bushel PR, Heinloth AN, Li J et al.: Blood gene expression signatures predict exposure levels. Proc. Natl Acad. Sci. USA 104, 18211-18216 (2007). ■ Interesting article demonstrating the potential of translational, genomic biomarkers.
22. Deng MC, Eisen HJ, Mehra MR et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6, 150-160 (2006).
23. Fang KC: Clinical utilities of peripheral blood gene expression profiling in the management of cardiac transplant patients. J. Immunotoxicol. 4, 209-217 (2007).
24. Tang Y, Xu H, Du X et al.: Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. 26, 1089-1102 (2006).
25. Moore DF, Li H, Jeffries N et al.: Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 111, 212-221 (2005).
26. Xu H, Tang Y, Liu DZ et al.: Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab. 28, 1320-1328 (2008).
27. Wang K, Zhang S, Marzolf B et al.: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl Acad. Sci. USA 106, 4402-4407 (2009).
28. Miyamoto M, Yanai M, Ookubo S, Awasaki N, Takami K, Imai R: Detection of cell-free, liver-specific mRNAs in peripheral blood from rats with hepatotoxicity: a potential toxicological biomarker for safety evaluation. Toxicol. Sci. 106, 538-545 (2008).
29. Heidecker B, Hare JM: The use of transcriptomic biomarkers for personalized medicine. Heart Fail. Rev. 12, 1-11 (2007).
30. von Stein P, Lofberg R, Kuznetsov NV et al.: Multigene ana lysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology 134, 1869-1881 (2008).
31. Fielden MR, Nie A, McMillian M et al.: Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 103, 28-34 (2008).
32. Ichimura T, Bonventre JV, Bailly V et al.: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142 (1998).
33. Shi L, Reid LH, Jones WD et al.: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
34. Guo L, Lobenhofer EK, Wang C et al.: Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol. 24, 1162-1169 (2006).
35. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB et al.: Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat. Biotechnol. 24, 1140-1150 (2006).
36. Canales RD, Luo Y, Willey JC et al.: Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 24, 1115-1122 (2006).
37. Fiehn O: Metabolomics: the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155-171 (2002).
38. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical ana lysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
39. Lindon JC, Nicholson JK, Everett JR: NMR spectroscopy of biofluids. In: Annual Review of NMR Spectroscopy. Webb GA (Ed.). Academic Press, SD, USA, 2-88 (1999).
40. Chan EC, Koh PK, Mal M et al.: Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361 (2009).
41. Sreekumar A, Poisson LM, Rajendiran TM et al.: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
42. Craig A, Sidaway J, Holmes E et al.: Systems toxicology: integrated genomic, proteomic and metabonomic ana lysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res. 5, 1586-1601 (2006).
43. Coen M, Hong YS, Clayton TA et al.: The mechanism of galactosamine toxicity revisited; a metabonomic study. J. Proteome Res. 6, 2711-2719 (2007).
44. Robertson DG, Datta K, Wells D et al.: Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase. Chem. Res. Toxicol. 20, 1871-1877 (2007).
45. Sun J, Schnackenberg LK, Holland RD et al.: Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 328-340 (2008).
46. Chan W , Cai Z: Aristolochic acid induced changes in the metabolic profile of rat urine. J. Pharm. Biomed. Anal. 46, 757-762 (2008).
47. Espandiari P, Zhang J, Schnackenberg LK et al.: Age-related differences in susceptibility to toxic effects of valproic acid in rats. J. Appl. Toxicol. 28, 628-637 (2008).
48. Wei L, Liao P, Wu H et al.: Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum. Toxicol. Appl. Pharmacol. 227, 417-429 (2008).
49. 1H-NMR spectroscopy. J. Toxicol. Environ. Health Pt A 72, 374-384 (2009).
50. Schnackenberg LK, Chen M, Sun J et al.: Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol. Appl. Pharmacol. 235, 25-32 (2009).
51. 1H NMR spectroscopy. Toxicol. Appl. Pharmacol. 234, 314-325 (2009).
52. Boudonck KJ, Mitchell MW, Nemet L et al.: Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37, 280-292 (2009).
53. Portilla D, Li S, Nagothu KK et al.: Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 69, 2194-2204 (2006).
54. Lindon JC, Nicholson JK, Holmes E et al.: Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187, 137-146 (2003).
55. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK: The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6, 691-699 (2005).
56. Ebbels TM, Keun HC, Beckonert OP et al.: Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6, 4407-4422 (2007).
57. Barba I, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D: Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopybased metabolomics. J. Cell Mol. Med. 12, 1477-1485 (2008).
58. Serkova NJ, Van RZ, Tobias M, Pitzer JE, Wilkinson JE, Stringer KA: Utility of magnetic resonance imaging and nuclear magnetic resonance-based metabolomics for quantification of inflammatory lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L152-L161 (2008).
59. Altmaier E, Ramsay SL, Graber A, Mewes HW, Weinberger KM, Suhre K: Bioinformatics ana lysis of targeted metabolomics - uncovering old and new tales of diabetic mice under medication. Endocrinology 149, 3478-3489 (2008).
60. van Ginneken V, Verhey E, Poelmann R et al.: Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis. Biochim. Biophys. Acta 1771, 1263-1270 (2007).
61. Holmes E, Tsang TM, Tabrizi SJ: The application of NMR-based metabonomics in neurological disorders. NeuroRx 3, 358-372 (2006).
62. 1H NMR spectroscopy. J. Proteome Res. 5, 483-492 (2006).
63. Moolenaar SH, Engelke UF, Wevers RA: Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann. Clin. Biochem. 40, 16-24 (2003).
64. Kim K, Aronov P, Zakharkin SO et al.: Urine metabolomics ana lysis for kidney cancer detection and biomarker discovery. Mol. Cell. Proteomics 8, 558-570 (2009).
65. Spratlin JL, Serkova NJ, Eckhardt SG: Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440 (2009).
66. Wishart DS: Metabolomics: a complementary tool in renal transplantation. Contrib. Nephrol. 160, 76-87 (2008).
67. Barba I, de LG, Martin E et al.: Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Reson. Med. 60, 27-32 (2008).
68. Coen M, O'Sullivan M, Bubb WA, Kuchel PW, Sorrell T: Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. Clin. Infect. Dis. 41, 1582-1590 (2005).
69. 1H-NMR- based metabonomics. Nat. Med. 8, 1439-1444 (2002).
70. 1H NMR study. NMR Biomed. 18, 24-33 (2005).
71. Maguire G, Lee P, Manheim D, Boros L: SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. Expert Opin. Drug Discov. 1, 351-359 (2006).
72. Koulman A, Lane GA, Harrison SJ, Volmer DA: From differentiating metabolites to biomarkers. Anal. Bioanal. Chem. 394, 663-670 (2009). ■ Discusses the need to validate metabolic biomarkers and its associated challenges.
73. Yang J, Zhao X, Liu X et al.: High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J. Proteome Res. 5, 554-561 (2006).
74. Spivey JR, Bronk SF, Gores GJ: Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J. Clin. Invest. 92, 17-24 (1993).
75. Yin P, Zhao X, Li Q, Wang J, Li J, Xu G: Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J. Proteome Res. 5, 2135-2143 (2006).
76. Soga T, Baran R, Suematsu M et al.: Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281, 16768-16776 (2006).
77. Beger RD, Holland RD, Sun J et al.: Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr. Nephrol. 23(6), 977-984 (2008).
78. Wishart DS: Metabolomics in monitoring kidney transplants. Curr. Opin. Nephrol. Hypertens. 15, 637-642 (2006). ■ Interesting article that demonstrates how metabolomics analyses can be applied to monitor patients following kidney transplantation.
79. Clayton TA, Lindon JC, Everett JR et al.: An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria. Arch. Toxicol. 77, 208-217 (2003).
80. Clayton TA, Lindon JC, Everett JR et al.: Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: their relationship to one another, to liver damage and to weakened nutritional status. Arch. Toxicol. 78, 86-96 (2004).
81. Schnackenberg LK, Dragan YP, Reily MD, Robertson DG, Beger RD: Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants. Metabolomics 3, 87-100 (2007).
82. Woo HM, Kim KM, Choi MH et al.: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin. Chim. Acta 400, 63-69 (2009).
83. Beger R, Schnackenberg L, Holland R, Li D, Dragan Y: Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2, 125-134 (2006).
84. Saude EJ, Obiefuna IP, Somorjai RL et al.: Metabolomic biomarkers in a model of asthma exacerbation: urine nuclear magnetic resonance. Am. J. Respir. Crit. Care Med. 179, 25-34 (2009).
85. Li X, Xu Z, Lu X et al.: Comprehensive two-dimensional gas chromatography/ time-of-flight mass spectrometry for metabonomics: biomarker discovery for diabetes mellitus. Anal. Chim. Acta 633, 257-262 (2009).
86. 1H NMR spectroscopy. J. Proteome Res. 6, 3456-3464 (2007).
87. Goodsaid FM , Frueh FW: Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 9, E105-E108 (2007).
88. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653-683 (2008). ■ Comprehensive article that provides a good overview of metabolomics, including analytical platforms, informatics tools and potential applications of the technology.
89. Wishart DS: Applications of metabolomics in drug discovery and development. Drugs R. D. 9, 307-322 (2008).
90. Trygg J, Holmes E, Lundstedt T: Chemometrics in metabonomics. J. Proteome Res. 6, 469-479 (2007).
91. Wishart DS: Quantitative metabolomics using NMR. Trends Analyt. Chem 27, 228-237 (2008).
92. Clarke CJ , Haselden JN: Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol. 36, 140-147 (2008).
93. Brazma A, Hingamp P, Quackenbush J et al.: Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
94. Fiehn O, Robertson D, Griffin J et al.: The metabolomics standards initiative (MSI). Metabolomics 3, 175-178 (2007).
95. Sansone SA, Fan T, Goodacre R et al.: The metabolomics standards initiative. Nat. Biotechnol. 25, 846-848 (2007).
96. Evans RW, Williams GE, Baron HM et al.: The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5, 1553-1558 (2005).
97. Deverka PA: Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12, 149-157 (2009).
98. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63 (2009).
99. US FDA's Critical Path Report and List. www.fda.gov/oc/initiatives/ criticalpath
100. European Medicines Agency (EMEA): definition of a genomics biomarker. www.emea.europa.eu/pdfs/human/ ich/43798606en.pdf
101. European Medicines Agency (EMEA): rat urinary protein protein biomarkers announcement. www.emea.europa.eu/pdfs/human/ biomarkers/25088508en.pdf
102. Consortia: Critical Path Institute. www.c-path.org/consortia.cfm
103. ILSI: Health and Environmental Science Institute. www.hesiglobal.org/i4a/ pages/index. cfm?pageid=3279
104. FDA: Table of valid genomic biomarkers in the context of approved drug labels. www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ ucm083378.htm
105. Office of Biotechnology Activities: Report from the Department of Health and Human Services USA. http://oba.od.nih.gov/oba/SACGHS/reports/ SACGHS-PGx-report.pdf